Comparative Pharmacology
Head-to-head clinical analysis: ETHAMBUTOL HYDROCHLORIDE versus LAMPRENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHAMBUTOL HYDROCHLORIDE versus LAMPRENE.
ETHAMBUTOL HYDROCHLORIDE vs LAMPRENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits arabinosyl transferase (emb) involved in cell wall synthesis of mycobacteria, specifically inhibiting polymerization of arabinose into arabinan, a component of arabinogalactan.
Clofazimine binds preferentially to mycobacterial DNA, inhibiting replication and exerting antimicrobial activity. It also has anti-inflammatory properties by modulating immune responses.
15 mg/kg orally once daily (range 15-25 mg/kg); typically 800-1600 mg daily.
300 mg orally once daily in combination with other antimycobacterial agents.
None Documented
None Documented
3–4 hours in normal renal function; prolonged to 7–15 hours in moderate renal impairment and up to 30 hours in severe renal impairment; clinical context: requires dosing adjustment when creatinine clearance <30 mL/min.
Terminal elimination half-life ranges from 8 to 70 days (mean approximately 14 days) due to extensive tissue storage and slow release; may be longer with chronic dosing.
Renal: ~80% as unchanged drug and metabolites via glomerular filtration and tubular secretion; fecal: ~15%; biliary: <2%.
Primarily fecal (unabsorbed drug and biliary excretion); renal excretion accounts for <1% of the dose as unchanged drug and metabolites.
Category A/B
Category C
Antimycobacterial
Antimycobacterial